The role of proto-oncogene Fra-1 in remodeling the tumor microenvironment in support of breast tumor cell invasion and progression

Oncogene

Volumn 29, Issue 5, 2010, Pages 662-673

  Luo, Y P ^a,b   Zhou, H ^a   Krueger, J ^a   Kaplan, C ^a   Liao, D ^a   Markowitz, D ^a   Liu, C ^a   Chen, T ^a,b   Chuang, T H ^a   Xiang, R ^a,c   Reisfeld, R A ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b CHONGQING MEDICAL UNIVERSITY   (China)

^c NANKAI UNIVERSITY   (China)

Author keywords

Fra 1; IL 6 JAK Stat3 signaling pathway; Tumor microenvironment; Tumor associated macrophages

Indexed keywords

GELATINASE B; INTERLEUKIN 6; JANUS KINASE; STAT3 PROTEIN; TRANSCRIPTION FACTOR FRA 1; TRANSFORMING GROWTH FACTOR BETA; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREAST CANCER; BREAST TUMOR; CANCER INVASION; CANCER MODEL; CELL INTERACTION; CONTROLLED STUDY; FEMALE; FRA 1 PROTO ONCOGENE; METASTASIS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN SECRETION; PROTO ONCOGENE; SIGNAL TRANSDUCTION; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; UPREGULATION;

ANIMALS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL COMMUNICATION; CELL SEPARATION; DISEASE PROGRESSION; FEMALE; FLOW CYTOMETRY; FLUORESCENT ANTIBODY TECHNIQUE; MACROPHAGES; MICE; NEOPLASM INVASIVENESS; NEOVASCULARIZATION, PATHOLOGIC; PROTO-ONCOGENE PROTEINS C-FOS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 76349121520     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2009.308     Document Type: Article

References (35)

1. Adiseshaiah P, Peddakama S, Zhang Q, Kalvakolanu DV, Reddy SP. (2005). Mitogen regulated induction of FRA-1 proto-oncogene is controlled by the transcription factors binding to both serum and TPA response elements. Oncogene 24: 4193-4205.
2. Allavena P, Sica A, Solinas G, Porta C, Mantovani A. (2008). The inflammatory micro-environment in tumor progression: the role of tumor-associated macrophages. Crit Rev Oncol Hematol 66: 1-9.
3. Asschert JG, de Vries EG, De JS, Withoff S, Vellenga E. (1999). Differential regulation of IL-6 promoter activity in a human ovarian-tumor cell line transfected with various p53 mutants: involvement of AP-1. Int J Cancer 81: 236-242.
4. Balkwill F, Charles KA, Mantovani A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217.
5. Bronte V, Zanovello P. (2005). Regulation of immune responses by l-arginine metabolism. Nat Rev Immunol 5: 641-654.
6. Condeelis J, Pollard JW. (2006). Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124: 263-266.
7. Coussens LM, Tinkle CL, Hanahan D, Werb Z. (2000). MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 103: 481-490.
8. Darnell Jr JE. (2002). Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740-749.
9. Faggioli L, Costanzo C, Donadelli M, Palmieri M. (2004). Activation of the Interleukin-6 promoter by a dominant negative mutant of c-Jun. Biochim Biophys Acta 1692: 17-24.
10. Fraser CC, Chen BP, Webb S, van RN, Kraal G. (1995). Circulation of human hematopoietic cells in severe combined immunodeficient mice after Cl2MDP-liposome-mediated macrophage depletion. Blood 86: 183-192.
11. Gao SP, Mark KG, Leslie K, Pao W, Motoi N, Gerald WL, et al. (2007). Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas. J Clin Invest 117: 3846-3856.
12. Guiducci C, Vicari AP, Sangaletti S, Trinchieri G, Colombo MP. (2005). Redirecting in vivo elicited tumor infiltrating macrophages and dendritic cells towards tumor rejection. Cancer Res 65: 3437-3446.
13. Hagemann T, Robinson SC, Schulz M, Trumper L, Balkwill FR, Binder C. (2004). Enhanced invasiveness of breast cancer cell lines upon co-cultivation with macrophages is due to TNF-alpha dependent up-regulation of matrix metalloproteases. Carcinogenesis 25: 1543-1549.
14. Hiratsuka S, Watanabe A, Aburatani H, Maru Y. (2006). Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis. Nat Cell Biol 8: 1369-1375.
15. Hodge DR, Hurt EM, Farrar WL. (2005). The role of IL-6 and STAT3 in inflammation and cancer. Eur J Cancer 41: 2502-2512.
16. Knudsen E, Iversen PO, van RN, Benestad HB. (2002). Macrophage-dependent regulation of neutrophil mobilization and chemotaxis during development of sterile peritonitis in the rat. Eur J Haematol 69: 284-296.
17. Kortylewski M, Kujawski M, Wang T, Wei S, Zhang S, Pilon-Thomas S, et al. (2005). Inhibiting Stat3 signaling in the hematopoietic system elicits multicomponent antitumor immunity. Nat Med 11: 1314-1321.
18. Kortylewski M, Yu H. (2008). Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 20: 228-233.
19. Leek RD, Harris AL. (2002). Tumor-associated macrophages in breast cancer. J Mammary Gland Biol Neoplasia 7: 177-189.
20. Lewen S, Zhou H, Hu HD, Cheng T, Markowitz D, Reisfeld RA, et al. (2008). A Legumain-based minigene vaccine targets the tumor stroma and suppresses breast cancer growth and angiogenesis. Cancer Immunol Immunother 57: 507-515.
21. Lewis CE, Pollard JW. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612.
22. Lin EY, Li JF, Bricard G, Wang W, Deng Y, Sellers R, et al. (2007). Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol Oncol 1: 288-302.
23. Lin EY, Nguyen AV, Russell RG, Pollard JW. (2001). Colony-stimulating factor 1 promotes progression of mammary tumors to malignancy. J Exp Med 193: 727-740.
24. Lin EY, Pollard JW. (2007). Tumor-associated macrophages press the angiogenic switch in breast cancer. Cancer Res 67: 5064-5066.
25. Luo Y, Zhou H, Krueger J, Kaplan C, Lee SH, Dolman C, et al. (2006). Targeting tumor-associated macrophages as a novel strategy against breast cancer. J Clin Invest 116: 2132-2141.
26. Mantovani A, Schioppa T, Porta C, Allavena P, Sica A. (2006). Role of tumor-associated macrophages in tumor progression and invasion. Cancer Metastasis Rev 25: 315-322.
27. Martinez FO, Sica A, Mantovani A, Locati M. (2008). Macrophage activation and polarization. Front Biosci 13: 453-461.
28. Milde-Langosch K. (2005). The Fos family of transcription factors and their role in tumourigenesis. Eur J Cancer 41: 2449-2461.
29. Philips A, Teyssier C, Galtier F, Rivier-Covas C, Rey JM, Rochefort H, et al. (1998). FRA-1 expression level modulates regulation of activator protein-1 activity by estradiol in breast cancer cells. Mol Endocrinol 12: 973-985.
30. Pollard JW. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78.
31. Sica A, Schioppa T, Mantovani A, Allavena P. (2006). Tumour-associated macrophages are a distinct M2 polarised population promoting tumour progression: potential targets of anti-cancer therapy. Eur J Cancer 42: 717-727.
32. van RN, Sanders A. (1994). Liposome mediated depletion of macrophages: mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.
33. Yu H, Kortylewski M, Pardoll D. (2007). Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 7: 41-51.
34. Zajchowski DA, Bartholdi MF, Gong Y, Webster L, Liu HL, Munishkin A, et al. (2001). Identification of gene expression profiles that predict the aggressive behavior of breast cancer cells. Cancer Res 61: 5168-5178.
35. Zerbini LF, Wang Y, Cho JY, Libermann TA. (2003). Constitutive activation of nuclear factor kappaB p50/p65 and Fra-1 and JunD is essential for deregulated interleukin 6 expression in prostate cancer. Cancer Res 63: 2206-2215.